Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000548415 | SCV000658604 | uncertain significance | Hyperkalemic periodic paralysis | 2024-05-15 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 204 of the SCN4A protein (p.Ala204Val). This variant is present in population databases (rs199859508, gnomAD 0.08%). This variant has not been reported in the literature in individuals affected with SCN4A-related conditions. ClinVar contains an entry for this variant (Variation ID: 477430). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV005004248 | SCV002778432 | uncertain significance | Potassium-aggravated myotonia; Paramyotonia congenita of Von Eulenburg; Hypokalemic periodic paralysis, type 2; Hyperkalemic periodic paralysis; Congenital myasthenic syndrome 16; Congenital myopathy 22A, classic; Congenital myopathy 22B, severe fetal | 2024-04-17 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003139865 | SCV003821295 | uncertain significance | not provided | 2019-05-08 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003139865 | SCV005412809 | uncertain significance | not provided | 2024-07-30 | criteria provided, single submitter | clinical testing | PP3_moderate |